Compare iShares Russell 2000 ETF (IWM) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Organon & Co. Common Stock — how do they compare? iShares Russell 2000 ETF trades at $271.92 (market cap $77.75B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares Russell 2000 ETF is far larger — about 21.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Organon & Co. Common Stock for 0 Days on average.
| IWM | OGN | |
|---|---|---|
Market Cap | $77.75B | $3.62B |
Volume | 27,728,271 | 2,892,999 |
52-Week High | $305.06 | $13.81 |
52-Week Low | $229.13 | $5.70 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $276.71, down 0.42% with bearish technical signals from moving averages. The ETF faces headwinds as small-caps underperform large-caps, with recent Fed rate hikes pressuring the sector. Technical indicators show oversold conditions with RSI at 38.61, while support sits at $276. Recent news highlights IWM's decade-long underperformance versus the S&P 500, raising questions about the small-cap premium.
The outlook remains cautious given macroeconomic pressures and sector rotation away from small-caps. Higher interest rates typically disadvantage small companies with greater borrowing needs, while broader market concentration in tech giants reduces small-cap participation. However, current valuations may offer long-term value if economic conditions stabilize.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
